{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=65",
    "query": {
      "condition": "Disorders, Lymphoproliferative",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 7746,
    "total_pages": 775,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T18:23:11.519Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005906",
      "title": "Treatment With Octreotide in Patients With Lymphangioleiomyomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphangioleiomyomatosis",
        "Lymphangiomyomas",
        "Pleural Effusions",
        "Ascites"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2010-04-30",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005906"
    },
    {
      "nct_id": "NCT00505921",
      "title": "Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Campath-1H",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "BCNU",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "DRUG"
        },
        {
          "name": "Preparative Regimen for Allogenic Stem Cell Transplantation",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Low dose total body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2003-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-11-16",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505921"
    },
    {
      "nct_id": "NCT00464633",
      "title": "Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "alvocidib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2007-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 13,
      "location_summary": "San Diego, California • San Francisco, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464633"
    },
    {
      "nct_id": "NCT04569032",
      "title": "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2020-11-12",
      "completion_date": "2026-01-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569032"
    },
    {
      "nct_id": "NCT00113932",
      "title": "UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "High-Dose Density Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2003-12",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2011-09-02",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113932"
    },
    {
      "nct_id": "NCT00900198",
      "title": "Collection of Tissue Samples for Cancer Research",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms",
        "Lymphomas",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Months and older"
      },
      "enrollment_count": 5000,
      "start_date": "2006-07-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 16,
      "location_summary": "Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900198"
    },
    {
      "nct_id": "NCT01125787",
      "title": "Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)"
      ],
      "interventions": [
        {
          "name": "ofatumumab + bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nevada Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2010-05",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2011-07-20",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Las Vegas, Nevada",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125787"
    },
    {
      "nct_id": "NCT00014664",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "apolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PDL BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 1,
      "location_summary": "Freemont, California",
      "locations": [
        {
          "city": "Freemont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014664"
    },
    {
      "nct_id": "NCT00295932",
      "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2005-12-13",
      "completion_date": "2018-03-11",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295932"
    },
    {
      "nct_id": "NCT06846463",
      "title": "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "DLBCL - Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2025-05-27",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-11-22T18:23:11.519Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846463"
    }
  ]
}